Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Many people who struggle with weight management may experience an uncontrollable, near-obsessive preoccupation with food. | ...

Flush with new business, Philadelphia-based CDMO PCI Pharma Services is blueprinting multiple manufacturing outlays on both ...

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a ...

After several years spent honing its robotic cell therapy manufacturing system, Multiply Labs has snared its first ...

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...

Savara says it will in the first of half next year seek an FDA license to treat autoimmune pulmonary alveolar proteinosis ...

After circling Novo Nordisk and its high GLP-1 drug prices for months, Sen. | Ahead of a hearing on Ozempic and Wegovy prices ...

As CDMOs across the industry continue to face pressure from a fluctuating biopharma business environment, AGC Biologics is ...

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of ...